On September 2, Twist Bioscience Corp fell 5.01% in regular trading, trading at $132.12 per share, with turnover of $106 million. The stock has pulled back sharply from recent highs near $155, extending a multi-session decline amid notable insider selling activity.

Multiple Form 144 filings for proposed securities sales were disclosed in late August, including a holding change statement by CEO Emily Leproust filed on August 28. The selling pressure follows a roughly 17% single-day surge on August 20, when the company announced its selection by Anthropic as an independent evaluator for a multi-arm AI-driven protein design project. In addition, the company had previously filed a shelf registration in June for the potential sale of up to $200 million in common stock under an at-the-market program, compounding dilution concerns.

Within the Biotechnology sector, the broader industry showed gains on the session, with Moderna up 6.65%, Gilead Sciences up 1.74%, AbbVie up 1.53%, Amgen up 1.50%, and bioAffinity Technologies up 44.96%, contrasting with Twist Bioscience Corp's decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)